Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF

Publication | Open Access

DOI Full Paper Access

Citations

References

2014

Year

Bruno Chauffert, L. Feuvret, Franck Bonnetain, Luc Taillandier, Didier Frappaz, H. Taillia, Roland Schött, Jérôme Honnorat, Michel Fabbro, Isabelle Tennevet,

Annals of Oncology

Temavir StudyNeuro-oncologyTemozolomide-based ChemoradiationOncologyRadiation TherapyGliomaMedicineAnti-cancer AgentHigh-grade GliomasCancer TreatmentPharmacologyRadiation OncologyMolecular OncologyFinal Results